Data indicate that the same enzymatic activities, MMP-9 and isoQC, might be involved in the subsequent pE79-aSyn generation in PD and AD mouse models.
Abstract
The α-synuclein (aSyn) pathology is a predominant feature of synucleinopathies such as Parkinson's disease (PD). Triggers that may induce aSyn aggregation are not completely understood, but include post-translational modifications. One such modification is aSyn truncation exposing the N-terminal glutamine 79 residue that is subsequently converted into pyroglutamate (pE). The pE79-aSyn variant is prone to oligomerisation and thus highly neurotoxic. Here, we used a Thy1-aSyn PD mouse model overexpressing human wild type aSyn to reveal a possible spatial association of aSyn with matrix metalloproteinase-9 (MMP-9) as aSyn-truncating and with isoglutaminyl cyclase (isoQC) as pE-forming enzymes, respectively. We observed a cellular co-localisation of pE79-aSyn with MMP-9 and isoQC in aSyn overexpressing neurons in the substantia nigra. In addition, MMP-9 and GFAP protein expression increased during aging of Thy1-aSyn mice, whereas that of isoQC was reduced. In order to reveal potential cross-disease mechanisms of pE79-aSyn pathology, its cell type-specific appearance and immunohistochemical co-localisation with MMP-9 and isoQC was also evaluated in the tg2576 Alzheimer's disease (AD) mouse model. Here, a different cellular expression pattern with substantial co-localisation of pE79-aSyn with MMP-9, isoQC, QC and aSyn predominantly in amyloid plaque-surrounding astrocytes was detected. Together, these data indicate that the same enzymatic activities, MMP-9 and isoQC, might be involved in the subsequent pE79-aSyn generation in PD and AD mouse models. The cellular origins, however, differ between the mouse models with neuronal expression of aSyn and its modifying enzymes in the PD mouse model and astrocytic expression in the AD mouse model.
Overexpression of Kcnn1, a potassium channel subunit, appears to be neuroprotective in Parkinson’s Disease, and its action may have therapeutic implications.
Maria Nagy, W. Fenton, A. Horwich· Proceedings of the National...· 0 citations
A sensitive assay is developed in a human neuroblastoma model to assess expression levels and cytotoxicity of 3K and KLK αS, validating the sensitivity of the live-cell assay to detect pharmacological responses and highlighting the potential of engineered αS variants to model pathogenic features of PD.
Bao-Yi Li, A. K. Anderson, Heba Alnakhala et al.· Journal of Molecular Neurosc...· 0 citations
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease in the elderly population, characterized by a wide variety of motor and non-motor symptoms. Its complex biochemical and molecular mechanisms make it challenging to study PD directly in patients or to replicate it in vitro, underscoring the...
Iverson Conrado Bezerra, Maria Luiza de Lima Vitorino, Josivan Barbosa de Farias et al.· bioRxiv· 0 citations
The primary mechanism and subcellular localisation of α-synuclein toxicity in Parkinson’s disease pathogenesis remain unknown. We spatially and temporally resolved proteomic and transcriptomic changes in human iPSC-derived dopaminergic neurons with increasing burden of pathological α-synuclein. We found that misfolded...
Chor Lai Lam, N. Gatford, Ana Aragón-González et al.· Nature Communications· 0 citations
PrPC expression levels are identified as an important modulator of nigrostriatal vulnerability and neuroinflammatory phenotype in response to αSynO, supporting the hypothesis that PrPC contributes to αSynO-mediated pathogenic mechanisms.
Flavio de Souza Júnyor, F. Leser, Sarah de Souza Albuquerque et al.· Frontiers in Neuroscience· 0 citations
The deleterious effects of pS129 accumulation are demonstrated and a toxic role played by these aggregates are argued in favor of a toxic role played by these aggregates.
Amr Eed, Vladislav Novikov, Shahrzad Bahrampour et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.